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Orofacial cancers result in facial deformities and impairment of vital functions and are often
lethal. These aggressive solid tumors exhibit great heterogeneity between them and show distinct
and exclusive molecular alterations that deregulate the function of important signaling pathways.
The Notch signaling pathway is involved in the initiation and development of orofacial cancers.
Increasing evidence suggests that Notchmolecules may have a dual function in cancer, acting either
as oncogenes or tumor suppressor genes. Crosstalk between Notch and other signaling pathways
provides a critical multidirectional control in these cancers. Protein phosphorylation is activated
in cancers and therefore novel drugs inhibiting phosphorylation events (kinase inhibitors) are
increasingly used in the treatment of cancers. Another pharmacological strategy is the selective
targeting of Notch signaling in order to eliminate the cancer stem cells usingmonoclonal antibodies
against specific regions of the Notch molecules. Organoids, “organ-on-a-chip” devices and single-
cell genomic analyses could be used for further investigations and preclinical studies in orofacial
cancers. Organoids can be used to study complex interactions between the various cells lines
in orofacial cancers, as well as for the preclinical screening of novel drugs. Microfluidic culture
systems, also called “organs-on-chips,” can be used to model cancer cell behavior within orofacial
tissues and their environment. These chips also enable to vary drug delivery and composition in a
controlled manner in order to study cancer tissue responses to various pharmaceutical anticancer
products. Single-cell RNA-seq analyses allow exploring the genetic and functional heterogeneity
of orofacial cancers at a cellular resolution, thus revealing new insights into tumor composition
and drug resistance. These important technological developments and the innovative therapeutic
strategies demonstrate significant promise and generate enthusiasm and optimism within the
oncology community.
GENETIC ALTERATIONS AND NOTCH SIGNALING IN OROFACIAL
CANCERS
Head and neck squamous cell carcinomas (HNSCCs) are the sixth most common cancers
diagnosed worldwide and can result in facial deformities and impairment of vital functions such
as swallowing, speech, and taste (Porcheri et al., 2019). These solid tumors are aggressive and
often lethal (the eighth most common cause of cancer death) with a 5-years survival rate of 50%
of the cases (Nyman et al., 2018). The use of tobacco and excessive consumption of alcohol are
major risk factors for HNSCCs. Human papillomavirus (HPV) is an additional risk factor for
the development of HPV-associated HNSCCs. HPV-associated tumors exhibit distinct biological
features and patients have an overall improved survival rate (Nyman et al., 2018). HNSCCs
principally arise from a pre-neoplastic dysplasia that undergoes a series of genetic and epigenetic
modifications to progress toward malignancy. Although morphologically similar, HNSCCs exhibit
distinct and exclusive molecular alterations that deregulate the function of important signaling
pathways. HNSCCs exhibit many chromosomal abnormalities such as amplifications of region
11q13 that contains the cyclin D1 gene and region 7p11 that encodes epidermal growth factor
receptor (EGFR) (Agrawal et al., 2011).
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An involvement of NOTCH1 in human cancers was first
demonstrated through the discovery of translocations in T
cell leukemias (Ellisen et al., 1991). Subsequently, more
subtle mutations of NOTCH1 were identified in a variety of
hematopoietic and solid tumors (Grabher et al., 2006). The Notch
signaling pathway is evolutionary conserved and required for
cell fate decisions during embryogenesis and tissue regeneration
(Blanpain et al., 2006; Mitsiadis and Graf, 2009; Artavanis-
Tsakonas and Muskavitch, 2010). Notch signaling is activated
when the membrane-bound Notch receptors (Notch-1, -2, -3,
and -4) interact with their specific membrane-bound ligands
(Jagged-1, -2, Delta-like-1, -3, -4) on adjacent cells. In the oral
cavity, members of the Notch pathway are mainly confined
to the oral mucosa (Mitsiadis et al., 1995, 1997). Loss of
NOTCH1 in this tissue leads to oral epithelial dysplasias and
promotes tumor initiation while impairing barrier integrity
and generating a wound-like environment in the underlying
stroma (mesenchyme) (Sakamoto, 2016; Nyman et al., 2018).
Numerous other findings have also shown that reduced activity
of other components of the Notch pathway is associated with
the development of various cancers. Taken together, these
observations suggest that Notch signaling possesses a tumor
suppressor function rather than having an oncogene function. In
contrast, the large number of mutations in hematopoietic tumors
strongly implicates Notch molecules as tumor drivers. However,
the NOTCH1 mutations that have been observed in HNSCCs
were localized in the N-terminal epidermal growth factor (EGF)-
like ligand-binding domain and therefore are different from those
mutations identified in hematopoietic tumors. The location and
nature of these alterations provide solid genetic evidence that
NOTCH1 acts mainly as a tumor suppressor gene in HNSCCs
(Agrawal et al., 2011; Stransky et al., 2014; Lawrence et al., 2015).
Indeed, experiments in genetically modified mice with Notch1
deletion in epithelium have demonstrated that these animals
develop epithelial tumors (Nicolas et al., 2003). Therefore,
NOTCH1 may have a dual function in cancer, acting either as
an oncogene in several leukemia cases or as a tumor suppressor
gene in HNSCCs (Yap et al., 2015; Porcheri et al., 2019).
Bioinformatics analyses on HNSCCs have identified Notch1
as one of the genes (Lawrence et al., 2015), together with
several coding for receptor tyrosine kinases, that are frequently
affected by genomic alterations. Crosstalk of Notch signaling
with other molecular pathways is important in regulating
proliferative, apoptotic, and invasive processes (Porcheri et al.,
2019). Notch interacts with p53, a tumor suppressor protein
that can be activated by diverse stressful signals to ultimately
modulate cellular responses such as transient cell cycle arrest,
senescence and apoptosis (Porcheri et al., 2019). Experiments
in animal models have shown reduced p53 levels upon Notch1
activation (Porcheri et al., 2019). Crosstalk between Notch and
Wnt signaling occurs in various cancers where β-catenin/T-
cell factor/lymphoid enhancer factor (TCF) activates Notch
signaling that leads to the expression of Myc proto-oncogene
(Myc) (Porcheri et al., 2019). Activation of the Wnt pathway
can occur in absence of β-catenin in HNSCCs. Sonic Hedgehog
(SHH) signaling is also upregulated in HNSCCs and mutations
in this pathway have been found in basal cell carcinomas.
SHH increases the transcription of genes involved in the Notch
pathway, while Notch regulates the intracellular localization of
SHH (Porcheri et al., 2019). Collectively, these findings suggest a
critical multidirectional control of the various signaling pathways
within tumors, thus providing new insights that might accelerate
the progress in HNSCCs prevention and therapy.
INNOVATIVE THERAPEUTIC STRATEGIES
FOR OROFACIAL CANCERS
The different genetic landscapes, associated with tobacco
exposure, alcohol and HPV, are consistent with clinical and
epidemiologic data. These factors are important in prognosis
and response to therapeutic interventions (Porcheri et al., 2019).
Signaling networks that employ phosphorylation to regulate
cell activities are involved in cancer, where abnormal activation
of protein phosphorylation is frequently either a driver or
direct consequence of this disease (Gross et al., 2015). Kinase
signaling pathways are involved in many activities of tumor
tissues such as cell proliferation andmotility, as well as antitumor
immune responses. Therefore, novel therapeutic approaches are
focused in developing drugs to inhibit protein phosphorylation.
Small molecule kinase inhibitors with suitable pharmaceutical
properties are increasingly used in the treatment of cancers
(Gross et al., 2015). New oncology drugs that also target
kinases have been approved, and ongoing clinical trials are in
various stages of evaluation. Another therapeutic opportunity
may exist in modulating tumor immunity, which represents
a key mechanism in HNSCCs development (Michot et al.,
2016; Elicin et al., 2019). This important therapeutic strategy
has demonstrated significant promise within the cancer field.
While kinases play central roles in immune responses and could
therefore serve as relevant therapeutic tools, this field is still in
its infancy.
Cancer stem cells, which exhibit self-renewal and tumor-
initiating properties, are involved in chemotherapeutic drug
resistance. Deregulation of key epigenetic cues can shift
the balance toward oncogenic transformation, leading to
development and metastasis of HNSCCs. Understanding of
this epigenetic balance is critical for valid drug design and
accurate therapy. Epigenetic drugs (epidrugs) could be used in
combination with chemotherapy or immunotherapy in order
to reprogram cancer stem cells and sensitize to chemotherapy
(Albiges et al., 2015; Bais, 2019). Dysregulation of EGF activates
the immune system in HNSCCs, thus suggesting that EGF
mediators, epidrugs and chemotherapy could be used in synergy
for regulating immune responses, thus offering suitable andmore
appropriate therapeutic outcomes for HNSCCs (Bais, 2019).
Notch is a key player in regulating cancer stem cell
maintenance and mobility during metastasis (Artavanis-
Tsakonas andMuskavitch, 2010; Porcheri et al., 2019). Therefore,
one of the main pharmacological strategies is the selective
targeting of Notch signaling in order to eliminate the cancer
stem cells. Monoclonal antibodies either targeting specific
regions of the Notch ligand-receptor binding domain or blocking
the nuclear translocation of Notch (such as the molecule GSI
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DAPT) have been used in combined cancer treatments. This
treatment, as well as the combinatory use of Notch inhibitors
and chemotherapeutic drugs, resulted in a significant reduction
of cancer stem cells (Porcheri et al., 2019). However, the use of
these Notch-tailored molecules may cause severe side effects and
therefore requires periodic administration with lag phases for
patient recovery.
POTENTIAL USE OF NOVEL
TECHNOLOGICAL DEVELOPMENTS IN
OROFACIAL CANCER RESEARCH
Although these recent findings have contributed to a certain
molecular understanding of HNSCCs regulation, further
investigations on the differences between HNSCCs and other
cancer types and subtypes would surely increase the chances to
treat better this disease. Genetically modified and humanized
mouse models have been used to test epigenetic regulators
and other candidates in HNSCCs (Porcheri et al., 2019).
Recently developed tools such as organoids (Rossi et al., 2018),
“organ-on-a-chip” devices (Sontheimer-Phelps et al., 2019),
and single-cell genomic analyses (Puram et al., 2017) could be
used for further research and preclinical studies concerning
HNSCCs. Organoids are three-dimensional (3D) structures of
different organ-specific cell types derived from the culture of
primary stem cells that share many structural and molecular
features of the organ of interest (Baker, 2018; Rossi et al.,
2018). Organoids can emulate normal or pathological organ
structures and thus can be used to study complex interactions
between the various cells types in physiological and cancer
conditions. Organoids generated from patient samples can be
genetically engineered, thereby generating a unique system to
study HNSCCs initiation and progression. Organoids can be also
used for the preclinical screening of novel drugs against these
tumors. Recent developments in microfluidic culture systems
have led to the generation of human “organs-on-chips” that can
be used to model cancer cell behavior within orofacial tissues and
their microenvironment (Sontheimer-Phelps et al., 2019). These
chips enable to vary cellular, molecular and pharmaceutical cues
in a controlled manner while analyzing how these parameters
contribute to HNSCCs initiation, progression and responses
to various drug therapies. Advances in single-cell genomics
provide an exceptional tool to explore genetic and functional
HNSCCs heterogeneity at a cellular resolution (Puram et al.,
2017). These single-cell RNA-seq studies have revealed new
insights into tumor composition, cancer stem cells and drug
resistance. Epithelial-to-mesenchymal transition (EMT) markers
have been detected and associated with cancer metastatic events.
CONCLUSION
All these exciting recent developments generate enthusiasm and
optimism within the medical community that selective targeted
HNSCCs therapies will continue to improve and significantly
extend patients’ lives.
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